The National Centre for Drug Screening (NCDS) located in Shanghai, China and Cellomics have announced a joint collaboration aimed at expanding the application of HCS in China
Affiliated with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, the centre is a key national technology innovation base in drug discovery and development.
Cellomics, a privately held company, is recognised as the creator of and market leader in HCS, providing a unique cell-based platform to its global clients in pharmaceutical, biotechnology and academic institutions.
"We are very pleased to work with Cellomics as a strategic partner in the establishment of an HCS program at the centre," stated Ming-Wei Wang, director of the NCDS. "By including the ArrayScan HCS reader with Cellomics software, reagents and expertise in the implementation of HCS, we are able to quickly execute our strategic plan for including high content cell-based assays in our drug discovery and development efforts," continued Dr Wang.
"Our collaboration with Dr Wang and the NCDS is critically important for Cellomics," replied Daniel Calvo, president and CEO of Cellomics. "Through this joint effort with China's leading drug discovery facility, we can expand our global leadership position in HCS into China and the surrounding region.
"We look forward to assisting this world-class laboratory in incorporating our technology into their research programmes," continued Calvo.
